2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6062 Refining the ELN 2022 risk classification for secondary AML patients receiving allo-HSCT: Identification of an ultra-adverse subgroup

Nan Yang, Shan Jiang2, Dan Feng, MD3, Mingyang Wang4, Yigeng Cao II, MD, PhD5, Wenbin Cao6, Xin Chen7, Chen Liang8, Rongli Zhang9, Qiaoling MA10, Jialin Wei11, Weihua Zhai12, Donglin Yang13, Yi He, MD14, Mingzhe Han15, Didier Blaise, MD16, Er-Lie Jiang, MD17, Aiming Pang, MD18
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
16 Department of Hematology, Transplantation and Cell Therapy Program, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France, Marseille, France
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China, Tianjin, China
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for secondary acute myeloid leukemia (sAML), post-transplant relapse remains a major cause of treatment failure, highlighting the need for more accurate risk stratification. We retrospectively analyzed 126 adults with sAML who underwent myeloablative conditioning followed by allo-HSCT between January 2017 and December 2023. We evaluated the prognostic performance of the 2022 European LeukemiaNet (ELN) risk classification and the respective contributions of myelodysplasia-related cytogenetic abnormalities (MR-CG) and gene mutations (MR-GM) to post-transplant outcomes. After a median follow-up of 34.6 months, the 3-year overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and cumulative incidence of measurable residual disease relapse (CIR-MRD) were 68.4%, 63.5%, 15.8%, and 25.5%, respectively. Three-year OS was 100.0%, 71.9%, and 63.0% in the favorable-, intermediate-, and adverse-risk ELN 2022 groups, respectively (p = 0.064). No significant differences were observed in LFS, CIR, or CIR-MRD among the three groups (p = 0.061, p = 0.111, and p = 0.305, respectively), indicating limited prognostic discrimination. Within the adverse-risk category, MR-CG was associated with inferior LFS and higher CIR-MRD (p = 0.021 and p = 0.006, respectively), whereas MR-GM was not significantly associated with any evaluated post-transplant outcome. We therefore developed a refined ELN 2022 classification in which 34 patients harboring −5/del(5q), −7, −17/abn(17p), complex karyotype, inv(3)/t(3;3)/MECOM(EVI1) rearrangements, or TP53 mutations were classified as ultra-adverse, while the remaining 50 adverse-risk patients were classified as standard-adverse. The ultra-adverse subgroup had 3-year OS, LFS, CIR, and CIR-MRD rates of 46.2%, 37.8%, 38.4%, and 51.3%, respectively, and had significantly worse outcomes than the standard-adverse subgroup (p = 0.042, p = 0.008, p = 0.006, and p < 0.001, respectively). In multivariable analyses, the ultra-adverse subgroup was independently associated with inferior OS and LFS and higher CIR and CIR-MRD. These findings indicate that MR-CG contributes more strongly than MR-GM to post-transplant prognostic heterogeneity in sAML and support refinement of ELN 2022 risk stratification in the transplant setting.
Nan Yang: No relevant conflicts of interest to declare.